nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Acknowledgement to Referees
|
|
|
|
|
6 |
p. 323-325 |
artikel |
2 |
Acknowledgement to Referees
|
|
|
|
|
6 |
p. 319-321 |
artikel |
3 |
Acknowledgement to Referees
|
|
|
|
|
6 |
p. 363-364 |
artikel |
4 |
Acknowledgement to referees
|
|
|
|
|
6 |
p. 441-444 |
artikel |
5 |
American Geriatrics Society Annual Scientific Meeting (AGS 2023)
|
Herdson, Caroline |
|
|
|
6 |
p. 491-493 |
artikel |
6 |
Correction to: The Impact of the Priority Review Voucher on Research and Development for Tropical Diseases
|
Aerts, Celine |
|
|
|
6 |
p. 405 |
artikel |
7 |
Current Challenges in Labelling for Generic Medicinal Products: Company Core Data Sheet (CCDS) Development and Maintenance
|
Mueller, Marion |
|
|
|
6 |
p. 381-386 |
artikel |
8 |
Drug Repurposing for Spinal Cord Injury: Progress Towards Therapeutic Intervention for Primary Factors and Secondary Complications
|
Guha, Lahanya |
|
|
|
6 |
p. 463-490 |
artikel |
9 |
Effectiveness of Additional Risk Minimization Measures for Atezolizumab in the European Union
|
Patel, Hina |
|
|
|
6 |
p. 339-351 |
artikel |
10 |
Forum
|
|
|
|
|
6 |
p. 377-386 |
artikel |
11 |
Forum
|
|
|
|
|
6 |
p. 407-413 |
artikel |
12 |
Forum
|
|
|
|
|
6 |
p. 333-341 |
artikel |
13 |
Forum
|
|
|
|
|
6 |
p. 349-363 |
artikel |
14 |
Forum
|
|
|
|
|
6 |
p. 371-377 |
artikel |
15 |
Journal Watch
|
|
|
|
|
6 |
p. 387-396 |
artikel |
16 |
Journey from an Enabler to a Strategic Leader: Integration of the Medical Affairs Function in ESG Initiatives and Values
|
Furtner, Daniel |
|
|
|
6 |
p. 405-416 |
artikel |
17 |
Key Characteristics of Database Studies on Drug Effectiveness in the Postmarketing Stage: A Systematic Review
|
Shiragasawa, Chihaya |
|
|
|
6 |
p. 327-338 |
artikel |
18 |
Major Pharmaceutical Conferences and Courses: February to March 2023
|
|
|
|
|
6 |
p. 401-403 |
artikel |
19 |
Major Pharmaceutical Conferences and Courses: February to March 2022
|
|
|
|
|
6 |
p. 371-374 |
artikel |
20 |
Major Pharmaceutical Conferences and Courses: February to March 2021
|
|
|
|
|
6 |
p. 415-416 |
artikel |
21 |
Major Pharmaceutical Conferences and Courses: February 2024 to March 2024
|
|
|
|
|
6 |
p. 495-497 |
artikel |
22 |
Plain Language Summaries of Clinical Trial Results: A Preliminary Study to Assess Availability of Easy-to-Understand Summaries and Approaches to Improving Public Engagement
|
Penlington, Michael |
|
|
|
6 |
p. 401-406 |
artikel |
23 |
Potential Role of Polyphenolic Flavonoids as Senotherapeutic Agents in Degenerative Diseases and Geroprotection
|
Mbara, Kingsley C. |
|
|
|
6 |
p. 331-352 |
artikel |
24 |
Practical Considerations for the Implementation and Monitoring of Risk Minimisation Measures for High-Risk Teratogenic Medicines
|
Mueller, Marion |
|
|
|
6 |
p. 439-449 |
artikel |
25 |
Risk Minimisation Evaluation with Process Indicators and Behavioural or Health Outcomes in Europe: Systematic Review
|
Artime, Esther |
|
|
|
6 |
p. 387-400 |
artikel |
26 |
Strengthening the Cost Effectiveness of Medical Countermeasure Development Against Rare Biological Threats: The Ebola Outbreak
|
Johnson, Mark Lawrence |
|
|
|
6 |
p. 423-436 |
artikel |
27 |
Strengthening the Pharmacovigilance System in Mexico: Implementation of VigiFlow and VigiLyze, as ICSR and Signal Detection Management Systems
|
Rayón-Ramírez, Gandi |
|
|
|
6 |
p. 425-437 |
artikel |
28 |
37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2021): 13–15 October, 2021
|
Pochon, Sue |
|
|
|
6 |
p. 367-370 |
artikel |
29 |
The Characteristics of Clinical Trials on Cannabis and Cannabinoids: A Review of Trials for Therapeutic or Drug Development Purposes
|
Modaresi, Farhang |
|
|
|
6 |
p. 387-400 |
artikel |
30 |
The Effectiveness and Safety of Cannabidiol in Non-seizure-related Indications: A Systematic Review of Published Randomized Clinical Trials
|
Tang, Yuni |
|
|
|
6 |
p. 353-385 |
artikel |
31 |
The Emergence of Regulatory Science in Pharmaceutical Medicine
|
Callréus, Torbjörn |
|
|
|
6 |
p. 345-351 |
artikel |
32 |
The Pharmaceutical Year That Was, 2022
|
Fox, Anthony W. |
|
|
|
6 |
p. 327-330 |
artikel |
33 |
The Pharmaceutical Year that was, 2021
|
Fox, Anthony W. |
|
|
|
6 |
p. 323-325 |
artikel |
34 |
The Pharmaceutical Year That Was, 2020
|
Fox, Anthony W. |
|
|
|
6 |
p. 365-368 |
artikel |
35 |
The Pharmaceutical Year That Was, 2023
|
Fox, Anthony W. |
|
|
|
6 |
p. 401-404 |
artikel |
36 |
The Pharmacokinetics of Drugs Delivered to the Upper Nasal Space
|
Shrewsbury, Stephen B. |
|
|
|
6 |
p. 451-461 |
artikel |
37 |
The Unintended Consequences of Adverse Event Information on Medicines’ Risks and Label Content
|
Furlan, Giovanni |
|
|
|
6 |
p. 369-380 |
artikel |
38 |
The Value and Deliverables of Medical Affairs: Affiliate Perspectives and Future Expectations
|
Farrington, Anupma Dhanda |
|
|
|
6 |
p. 417-424 |
artikel |
39 |
To Tweet or Not to Tweet: A Longitudinal Analysis of Social Media Use by Global Diabetes Researchers
|
Leigh, Simon |
|
|
|
6 |
p. 353-365 |
artikel |